Drugs / Ovasave
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT02327221 Comparator | Dec 2014 → Nov 2016 | Crohn disease | TxCell | Terminated | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ovasave | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02327221 ↗ |
| Known as | Ova-Treg | “The investigational product, named Ovasave (Ova-Treg), is a cell-based therapy, consisting of an autologous antigen-specific regulatory type 1 T lymphocyte expanded population...” NCT02327221 ↗ |
| Modality | Cell therapy | “is a cell-based therapy” NCT02327221 ↗ |
| Route | Intravenous | “administered via the intravenous route as an infusion” NCT02327221 ↗ |